Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T17:03:27.332Z.
Calculation as of: 2026-10-06T17:03:27.332Z.
Quote observation: 2026-10-06T16:57:23.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 7269c43ec051f04bc9b25698fa87f96476c1bd81d443a59abbb4ab2a9593cf8e
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
NeuroSense Therapeutics Ltd.
Market Cap
$7.08M
EBITDA Yield
N/A
| NAME | MARKET CAP | EBITDA YIELD |
|---|---|---|
| NeuroSense Therapeutics Ltd. (NRSN) | $7.08M | N/A |
| Curanex Pharmaceuticals Inc Common Stock (CURX)vs › | $7.07M | N/A |
| KALA BIO, Inc. (KALA)vs › | $7.16M | N/A |
| Mangoceuticals, Inc. (MGRX)vs › | $7.00M | N/A |
| Bolt Biotherapeutics, Inc. (BOLT)vs › | $6.99M | N/A |
| Longeveron Inc. (LGVN)vs › | $7.27M | N/A |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.31M | N/A |
| Exicure, Inc. (XCUR)vs › | $6.82M | N/A |
| Aclarion, Inc. (ACON)vs › | $6.74M | N/A |
| Skye Bioscience, Inc. (SKYE)vs › | $7.40M | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
